Frederic Triebel

4PUBLICATIONS
33CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Dec 13, 2024
Crystal structure of the human LAG-3-HLA-DR1-peptide complex.

Jan Petersen, Carmen Llerena, Bagher Golzarroshan

|Jul 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

Martin Forster, Irene Brana, Antonio L Pousa

|Nov 08, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.

Hans Wildiers, Anne Armstrong, Eveline Cuypere

|Nov 21, 2020
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.

Victoria Atkinson, Adnan Khattak, Andrew Haydon

Pageof 1